Back to search results

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

Abroad (travel likely)RecruitingPHASE3

Conditions

Eosinophilic Esophagitis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Dr. Falk Investigational Site, Scottsdale, Arizona, United States

  • Dr. Falk Investigational Site, Little Rock, Arkansas, United States

  • Dr. Falk Investigational Site, La Jolla, California, United States

    Study coordinator · 858-824-4151

  • Dr. Falk Investigational Site, Lomita, California, United States

  • Dr. Falk Investigational Site, San Diego, California, United States

  • Dr. Falk Investigational Site, Doral, Florida, United States

  • Dr. Falk Investigational Site, New Port Richey, Florida, United States

  • Dr. Falk Investigational Site, Boise, Idaho, United States

    Study coordinator · 208-813-6505

  • Dr. Falk Investigational Site, Houma, Louisiana, United States

  • Dr. Falk Investigational Site, Marrero, Louisiana, United States

  • Dr. Falk Investigational Site, Boston, Massachusetts, United States

    Study coordinator · 617-804-6767

  • Wyoming, Ann Arbor, Michigan, United States

  • Dr. Falk Investigational Site, Plymouth, Michigan, United States

    Study coordinator · 612-870-5599

  • Dr. Falk Investigational Site, Wyoming, Michigan, United States

  • Dr. Falk Investigational Site, Rochester, Minnesota, United States

    Study coordinator · 507-284-2511

  • Dr. Falk Investigational Site, Freehold, New Jersey, United States

    Study coordinator · 504-934-8424

  • Dr. Falk Investigational Site, Jackson, New Jersey, United States

  • Dr. Falk Investigational Site, New York, New York, United States

  • Dr. Falk Investigational Site, Chapel Hill, North Carolina, United States

    Study coordinator · 919-966-2996

  • Dr. Falk Investigational Site, Cleveland, Ohio, United States

    Study coordinator · 216-444-7691

  • Dr. Falk Investigational Site, Mentor, Ohio, United States

  • Wyoming, Philadelphia, Pennsylvania, United States

  • Dr. Falk Investigational Site, Harlingen, Texas, United States

    Study coordinator · 956-377-4371

  • Dr. Falk Investigational Site, Salt Lake City, Utah, United States

    Study coordinator · 480-301-6292

  • Dr. Falk Investigational Site, Charlottesville, Virginia, United States

  • Dr. Falk Investigational Site, Lynchburg, Virginia, United States

  • Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain

    Contact: Study coordinator (Alfredo Lucendo, MD, PhD) · ajlucendo@hotmail.com · 0034926525
Study leads

  • Alfredo J Lucendo, MD, PhD

    Study Director

    Department of Gastroenterology, Hospital General de Tomelloso, Spain

View source on ClinicalTrials.gov(opens in a new tab)